Monitor for IND submission timeline and potential partnership interest in AVTX-010. The first-half 2027 IND target provides a long lead time; near-term focus should remain on abdakibart Phase 3 initiation and any data readouts.
Price Chart
Executive Summary
Avalo Therapeutics announced advancement of AVTX-010, a next-generation anti-IL-1β monoclonal antibody, with an IND submission planned for the first half of 2027. The molecule is designed for less frequent dosing in hidradenitis suppurativa and other inflammatory diseases, building on positive Phase 2 data for lead asset abdakibart. This pipeline expansion is a positive signal but remains early-stage with no near-term catalyst.
Key Facts
- AVTX-010 is a long-acting next-generation anti-IL-1β monoclonal antibody targeting hidradenitis suppurativa and other inflammatory disorders.
- IND submission for AVTX-010 is planned for the first half of 2027.
- Program builds on positive Phase 2 LOTUS topline data for lead asset abdakibart.
- Company completed a transformational financing in May 2026 to support pipeline advancement.
- Avalo is fully dedicated to IL-1β-based treatments for immune-mediated inflammatory diseases.
Financial Impact
No direct financial impact; pipeline expansion may support long-term valuation but no revenue or near-term catalyst.
Risk Factors
- Clinical development risk: AVTX-010 is preclinical; failure in Phase 1 or later trials could impair pipeline value.
- Regulatory risk: IND acceptance and subsequent trial approvals are uncertain.
- Competition: Existing IL-1β inhibitors (e.g., canakinumab, anakinra) may limit market opportunity.
- Financing risk: Despite recent financing, additional capital may be needed for Phase 3 and AVTX-010 development.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3312405 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 6w ago | Insider Cluster | $20.75 $16.69 | ▼ −19.57% | ▼ −17.61% | $14.99 (−27.76%) |
Aug 17, 2026 6w ago | Institutional Cluster | $19.95 $16.07 | ▼ −19.45% | ▼ −17.47% | $14.99 (−24.86%) |
Aug 6, 2026 8w ago | 8-K | $18.70 $19.00 | ▲ +1.60% | ▲ +1.00% | $14.99 (−19.84%) |
Jun 16, 2026 15w ago | 8-K | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 16, 2026 15w ago | Press Release | $14.33 $18.42 | ▲ +28.54% | ▲ +28.34% | $14.99 (+4.61%) |
Jun 8, 2026 16w ago | 8-K | $12.90 $19.25 | ▲ +49.22% | ▲ +47.78% | $14.99 (+16.20%) |
May 13, 2026 20w ago | 8-K | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 13, 2026 20w ago | Press Release | $19.85 $13.67 | ▼ −31.13% | ▼ −30.52% | $14.99 (−24.48%) |
May 6, 2026 21w ago | Press Release | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
May 6, 2026 21w ago | Insider Cluster | $21.81 $13.74 | ▲ +37.00% | ▲ +39.78% | $14.99 (+31.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access